Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Terminally differentiated stem cell-derived cells with negligible immunogenicity

Terminally differentiated stem cell-derived cells show negligible immunogenicity, suggesting they could be useful for transplant and cell therapy applications. Terminally differentiated mouse skin and bone marrow cells derived from 10 different induced pluripotent stem (iPS) cell and 7 embryonic stem cell (ESC) lines had limited or no immunogenicity after transplantation into immunocompetent mice. Next steps include conducting additional immunogenicity studies on ESC- and iPS cell-derived cells.

SciBX 6(4); doi:10.1038/scibx.2013.104
Published online Jan. 31, 2013

Unpatented; licensing status not applicable

Araki, R. et al. Nature; published online Jan. 9, 2013;
doi:10.1038/nature11807
Contact: Masumi Abe, National Institute of Radiological Sciences, Chiba, Japan
e-mail:
abemasum@nirs.go.jp